{"url_path":"/sec/tgtx/8-k/2026-01-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-01-13","source_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-001194-index.html","accession_number":"0001437749-26-001194","cik":"0001001316","ticker":"TGTX","issuer_name":"TG THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-001194-index.html","primary_entity_key":"0001001316","primary_entity_name":"TG THERAPEUTICS, INC."},"word_count":99,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n \n \n \n\n99.1\n\n \n\n[Press release issued by TG Therapeutics, Inc., dated January 13, 2026.](ex_907046.htm)\n\n​\n\n​\n\n​\n\nExhibit 104\n\n \n\nThe cover page from this Current Report on Form 8-K formatted in Inline XBRL.\n\n ​\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n​\n\nTG Therapeutics, Inc.\n\n​\n\n(Registrant)\n\nDate: January 13, 2026\n\nBy:\n\n/s/ Sean A. Power\n\n​\n\n​\n\n Sean A. Power\n\n​\n\n​\n\n Chief Financial Officer\n\n ​\n\n ​"}